About Surgilum
Surgilum is a company based in Wilmington (United States) founded in 2010 by Alan Brown. It operates as a B2B. Surgilum operates in a competitive market with competitors including CorneaGen, Avedro, EyeGate, Cellusion and EyeYon, among others.
- Headquarter Wilmington, United States
- Founders Alan Brown
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website surgilum.com
- Social X Facebook Instagram YouTube
Apps and channels of Surgilum
its YouTube channel Surgilūm has 33 subscribers and 17 videos.
Videos from Surgilum
The most watched videos on Surgilum's YouTube channel, Surgilūm (33 subscribers). Click a video to play it here.
More on Surgilūm.
People of Surgilum
1 people are tracked at Surgilum (1 in leadership).
| Name | Role | Group |
|---|---|---|
Alan Brown | Founder, CEO | Leadership |
Complete people profiles for Surgilum
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Surgilum
Surgilum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Avedro, EyeGate, Cellusion and EyeYon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases |
Detailed competitors of Surgilum
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Surgilum
Complete news archive for Surgilum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Surgilum
10 companies that operate in the same segment as Surgilum (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Surgilum
Surgilum was founded in 2010.
Surgilum is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Alan Brown is the current CEO of Surgilum. They have also founded this company.
Surgilum creates innovative technologies for ophthalmic surgical devices through providing healthcare solutions, developing medical devices, surgical equipment, and ophthalmic technology. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.